The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CING | -20.71% | N/A | N/A | -100% |
| S&P | +13.66% | +87.02% | +13.34% | +42% |
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.11M | 35.4% |
| Market Cap | $21.22M | 93.1% |
| Market Cap / Employee | $1.63M | 0.0% |
| Employees | 13 | 0.0% |
| Net Income | -$7.34M | -127.2% |
| EBITDA | -$5.89M | -89.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.12M | -39.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.16M | 0.0% |
| Short Term Debt | $3.42M | 1358.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -183.12% | -15.0% |
| Return On Invested Capital | -120.90% | 67.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.24M | -13.4% |
| Operating Free Cash Flow | -$4.24M | -9.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.25 | 1.96 | 2.63 | 3.48 | 172.51% |
| Price to Tangible Book Value | 1.25 | 1.96 | 2.63 | 3.48 | 172.51% |
| Enterprise Value to EBITDA | -1.60 | -3.18 | -3.45 | -3.35 | -1256.86% |
| Return on Equity | -5305.0% | -358.1% | -417.8% | -284.5% | 3.90% |
| Total Debt | $5.10M | $5.08M | $6.58M | $4.58M | 1855.30% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
